|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 08-14 | Cerenome, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 08-02 | Plus Therapeutics, Inc. will Change its Name to Cerenome | CI |
| Market Cap | 22.47M 19.25M 18.01M 16.47M 31.07M 2.15B 31.4M 213M 82.87M 1.08B 84.35M 82.52M 3.57B | P/E 2026 * |
-0.59x | P/E 2027 * | -1.24x |
|---|---|---|---|---|---|
| Enterprise Value | 22.47M 19.25M 18.01M 16.47M 31.07M 2.15B 31.4M 213M 82.87M 1.08B 84.35M 82.52M 3.57B | EV / Sales 2026 * |
2.38x | EV / Sales 2027 * | 1.17x |
| Free-Float |
98.2% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cytori Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 64 | 2014-04-01 |
Andrew Sims
DFI | Director of Finance/CFO | 52 | 2020-02-05 |
Daniel Ortega
CTO | Chief Tech/Sci/R&D Officer | - | 2025-10-20 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
BRD | Director/Board Member | 64 | 2002-09-30 |
Richard Hawkins
CHM | Chairman | 77 | 2018-01-24 |
| Director/Board Member | 66 | 2019-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.82% | +4.81% | +3.53% | +25.29% | 51.21B | |
| +1.01% | -0.20% | +471.68% | +564.93% | 45.35B | |
| +0.16% | +7.88% | +36.14% | +20.76% | 42.84B | |
| -0.66% | +2.61% | +18.59% | +87.04% | 42.29B | |
| +0.88% | -3.48% | +17.20% | +53.83% | 32.15B | |
| -0.12% | +3.84% | +33.73% | +145.25% | 17.31B | |
| -0.53% | +1.84% | - | - | 16.55B | |
| +0.14% | +5.31% | +9.92% | +31.33% | 14.84B | |
| +1.15% | +4.17% | +84.49% | +50.33% | 14.25B | |
| Average | +0.31% | +3.23% | +84.41% | +122.34% | 30.75B | |
| Weighted average by Cap. | +0.36% | +3.07% | +101.42% | +141.83% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 9.44M 8.09M 7.57M 6.92M 13.06M 904M 13.19M 89.55M 34.82M 454M 35.44M 34.67M 1.5B | 19.14M 16.4M 15.35M 14.03M 26.48M 1.83B 26.76M 182M 70.61M 920M 71.87M 70.31M 3.05B |
| Net income | -34.22M -29.32M -27.43M -25.08M -47.33M -3.28B -47.83M -325M -126M -1.65B -128M -126M -5.44B | -18.45M -15.82M -14.8M -13.53M -25.53M -1.77B -25.8M -175M -68.08M -887M -69.29M -67.79M -2.94B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
